Why it matters
The result may inform research into treatment before surgery for people with colon cancer. It is a phase 2 finding, and the report does not establish that the regimen is approved or ready for routine care.
RESEARCH & TREATMENTS • UNITED STATES
Phase 2 trial reports major pathological responses with neoadjuvant immunotherapy for colon cancer
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
In the phase 2 UNICORN trial, a short course of botensilimab with or without balstilimab met its primary endpoint for pathological major response in patients with pMMR or dMMR colon cancer. The supplied report does not give response rates, safety details or evidence of improved long-term outcomes.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections